AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03246685 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imprime PGG
Description: Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
Study NCT03246685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
Study NCT02955537 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MI-BP
Description: MI-BP includes the following components: 1) Home blood pressure monitoring 2) Physical activity monitoring 3) Sodium intake self-monitoring 4) Physical activity and sodium intake goal setting 5) Educational messaging via push notification and in-app messaging 6) motivational messaging 7) tailored messaging relevant to individual participants and 8) medication reminders.
Study NCT02771197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Study NCT02771197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Study NCT02771197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT01794260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cream from Zingiber cassumunar Roxb. extract
Study NCT01794260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Study NCT03411421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-794
Description: AL-794 will be administered as tablets orally on Day 1 to Day 5.
Study NCT03411421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablets will be administered.
Study NCT03024125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High protein
Description: To observe the effect of a high protein (HP) diet over muscle mass, fat mass, and strength changes, focusing in differences between the NP and HP groups.
Study NCT03024125 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal protein
Description: To observe the effect of a normal protein (NP) diet over muscle mass, fat mass, and strength changes
Study NCT03024125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: The physical strength training will be performed equally by both groups, containing exercises for upper and lower limbs and aiming for hypertrophy.
Study NCT03024125 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Training
Description: The physical strength training will be performed equally by both groups, containing exercises for upper and lower limbs and aiming for hypertrophy.
Study NCT00386243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Cognitive behavioral therapy is delivered by phone by a nurse care-manager 6 times over a 12-week period. Sessions last approximately 45 minutes and occur at weeks 14, 16, 18, 20, 22, and 24 of the study.
Study NCT00386243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain self-management program
Description: The pain self-management program is delivered by a nurse care-manager during a 12-week period. Sessions are each 45 minutes long and phone-based. They occur at baseline, week 1, week 3, week 6, week 9, and week 12.
Study NCT00386243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-Analgesic Therapy
Description: Amitriptyline, start at 10-25, titrate to 100 mg Nortriptyline, start at 10-25, titrate to 100 mg~Gabapentin, titrate up to 900-1200 tid venlafaxine, carbemazepine, duloxetine, and/or pregabalin~Cyclobenzaprine, titrate to 10 mg TID fluoxetine, sertraline, citalopram
Study NCT00386243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid Analgesics
Description: Tramadol 50 mg BID or TID and titrate to 100 mg QID Acetaminophen/codeine (300mg/30mg). Take 1 or 2 tablets qid prn pain Acetaminophen/hydrocodone (500mg/5mg). Take 1 or 2 tablets qid prn pain Acetaminophen/oxycodone (500mg/5mg). Take 1 or 2 tablets qid prn pain Morphine SR (30mg). Start at 30 mg twice a day (titrate up to 240mg/day if needed) Methadone (5-10mg). Start at 5mg bid; titrate 10mg tid (max 20mg tid)
Study NCT03878680 — intervention group
Intervention type: OTHER
Intervention: Study questionnaires
Description: Completion of the International study of Asthma and Allergies in Children(ISAAC)core questionnaires:~1. Core questionnaire on wheezing.~2. Core questionnaire on rhinitis.~3. Core questionnaire on atopic dermatitis.
Study NCT02682992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: Patients will receive LLLT three times per week concurrently with chemoradiotherapy. LLLT may be delivered either immediately prior to or after the patient's daily fraction of radiotherapy. Patients will be treated extra-orally with a THOR® LED cluster for one minute along the buccal mucosa on each side and intraorally for one minute to the tongue and soft palate. During each LLLT treatment session a thorough oral exam will be performed to identify any areas of mucositis. If the patient should develop intraoral lesions they will be targeted directly with the intraoral probe for one minute to each site of mucositis. The laser settings to be used are as follows: frequency 2.5 Hz; wavelength 660 nm; and power 75 mW, for an energy of 4.5 J.
Study NCT01629758 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denenicokin
Study NCT01629758 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT03624595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine infusion is administered from 16:00 to 08:00 during the night of surgery in the intensive care unit; and will repeated for a maximum of 5 consecutive nights. For patients with mechanical ventilation, the infusion rate is 0.2-0.7 ug/kg/h; for those without mechanical ventilation, the infusion rate is 0.05-0.2 ug/kg/h. The target depth of sedation is Richmond Agitation-Sedation Scale (RASS) -1.
Study NCT03624595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (normal saline) infusion is administered in the same rate for the same duration as in the dexmedetomidine group. The conventional sedation is provided when necessary with propofol and/or midazolam by intravenous infusion/injection. The target depth of sedation depth is RASS -1.
Study NCT02363959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: 2 hours of breathing >99% medical grade oxygen inside an air-pressurized chamber at 2 ATA once a day for 20 sessions. These sessions will be scheduled 3-5 times per week, depending on the availability of the patient and the hyperbaric medicine physician.
Study NCT02363959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial Biopsy of Airway Epithelium
Description: During standard post-transplantation bronchoscopies, participants in this study will undergo an endobronchial biopsy of the airway epithelium for each donor lung.
Study NCT02363959 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endobronchial Biopsy of Airway Epithelium
Description: During standard post-transplantation bronchoscopies, participants in this study will undergo an endobronchial biopsy of the airway epithelium for each donor lung.
Study NCT03469791 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment of Degenerative Spondylolisthesis
Study NCT03421106 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Food Pantries
Description: Food pantries will receive consulting services to transform their food offerings and environment in order to influence client health behaviors.
Study NCT03421106 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Food Pantries
Description: Normal food pantry use
Study NCT04153682 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rapid Diagnostic Testing
Description: Automated microbiological diagnostic device based on multiplex PCR analysis, allowing detection of multiple pathogens and resistance markers in one hour from invasive and non-invasive respiratory samples
Study NCT04153682 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship
Description: After clinical examination, routine biological tests will be performed. This includes blood culture, direct examination and culture of invasive or noninvasive respiratory samples, urinary antigen tests for Legionella and Pneumococcus, Influenza PCR on nasopharyngeal swabs (during the influenza season).
Study NCT04153682 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Antimicrobial stewardship
Description: After clinical examination, routine biological tests will be performed. This includes blood culture, direct examination and culture of invasive or noninvasive respiratory samples, urinary antigen tests for Legionella and Pneumococcus, Influenza PCR on nasopharyngeal swabs (during the influenza season).
Study NCT00289926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dehydroepiandrosterone
Description: dehydroepiandrosterone capsules 50.0 mg /capsule DHEA 248.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule
Study NCT00289926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo capsules of 298.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule manufactured to mimic the active DHEA capsule
Study NCT03801226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Two-hour dwell with 10% dextrose in sterile water
Description: Patients will be randomized to undergo a two-hour dwell with 10% dextrose in sterile water at their first or second study visit and will receive the alternate intervention at the other study visit.
Study NCT03801226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Two-hour dwell with 10% dextrose in sterile water
Description: Patients will be randomized to undergo a two-hour dwell with 10% dextrose in sterile water at their first or second study visit and will receive the alternate intervention at the other study visit.
Study NCT03801226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose
Description: Patients will be randomized to undergo a two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose at their first or second study visit and will receive the alternate intervention at the other study visit.
Study NCT03801226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose
Description: Patients will be randomized to undergo a two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose at their first or second study visit and will receive the alternate intervention at the other study visit.
Study NCT04446065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Previfenon®
Description: Every capsule of Previfenon® (patent pending) provides 250 mg EGCG ≥ 98% purity with a carefully selected set of excipients to improve flowability, stabilize EGCG against early auto-oxidation, and increase its hepatoprotective activity with prolonged use.
Study NCT04446065 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo starch capsules (250 mg plus excipients) identical in appearance and taste to Previfenon® capsules in a double-blind manner.
Study NCT00112242 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melan-A ELA + Montanide
Description: A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months.
Study NCT00112242 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melan-A ELA + NY-ESO-1b + MAGE-A10 + Montanide
Description: A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months.
Study NCT04123405 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to acetylcysteine
Study NCT03692715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Oral or intravenous ciprofloxacin prior to shockwave lithotripsy.
Study NCT00112242 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melan-A -ELA + NY-ESO-1b + MAGE-A10 peptide + Montanide + CpG
Description: A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months.
Study NCT00112242 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG
Description: A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months.
Study NCT00112242 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG+ IL-2
Description: A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months.
Study NCT02284503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: The subjects will receive intensive Rosuvastatin before and after PCI
Study NCT00323414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyunsaturated fatty acid (Opti-EPA)
Description: Active experimental arm to patients with diabetes mellitus and non alcoholic steatohepatitis: Eicosapentaenoic acid (EPA):Docosahexaenoic acid (DHA)\[360 mg EPA and 240 DHA in each capsule\] 6 capsules-3 capsules by mouth 2 x per day x 48 weeks
Study NCT00323414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gelcaps containing corn oil identical to the PUFA gelcaps 6 capsules-3 capsules by mouth 2x per day x 48 weeks
Study NCT03161483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220
Study NCT03161483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo QD PO
Study NCT03161483 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo QD PO
Study NCT01503827 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBRT
Description: A minimum of 30 Gy in 10 fractions given as one fraction per day within 4 weeks of randomisation
Study NCT00744029 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: educational material
Description: Educational letter indicating stroke symptoms and emphasizing the importance of calling the emergency medical services (EMS) as well as a bookmark and sticker with the EMS telephone number.
Study NCT03692715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical oral placebo if oral cipro was used, or intravenous saline alone in a blinded fashion if IV cipro was used prior to shockwave lithotripsy.
Study NCT00733005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Description: MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
Study NCT00733005 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo nasal spray
Description: Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
Study NCT04038580 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Laminated Socket
Description: This is the currently prescribed socket the participant normally wears.
Study NCT04038580 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quatro
Description: The Quatro (Quorum) is one of three commercially available adjustable sockets used in this study that will be fit by a certified prosthetist.
Study NCT04038580 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infinite Socket
Description: The Infinite Socket (LiM Innovations) is one of three commercially available adjustable sockets used in this study that will be fit by a certified prosthetist.
Study NCT04038580 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CJ Socket
Description: The CJ Socket (CJ Socket Technologies) is one of three commercially available adjustable sockets used in this study that will be fit by a certified prosthetist.
Study NCT01094704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium chloride (7%)
Description: 4mL nebulized 7% sodium chloride
Study NCT00003199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Given orally
Study NCT00003199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given orally
Study NCT00003199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: Given IV
Study NCT00003199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV
Study NCT01707667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prucalopride
Description: One 2 mg tablet orally administered on Day 1
Study NCT01707667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG 3350
Description: 13.8g polyethylene glycol (PEG) 3350 with sodium bicarbonate, sodium chloride, and potassium chloride as a solution in water. Administered twice orally on Day 1(once in the morning and once prior to lunch).
Study NCT04506658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-frequency radio wave electrotherapy with a frequency of 448 kHz on the penis structures.
Description: Patient in lithotomy position (supine) with return plate at lumbar level.~Start with high power (within the allowed range) to get a faster hyperthermia and slowly decrease this percentage as the current builds up in the patient's body.~Patients are undergoing high-frequency radio wave electrotherapy 2 times a week (12 procedures at all).
Study NCT04506658 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: high-frequency radio wave electrotherapy with a frequency of 448 kHz on the penis structures.
Description: Doctor uses sham sensor to reduce efficiency to zero.
Study NCT02868294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fassier-Duval Nail
Description: Implementation of a telescopic system intramedullary
Study NCT00003199 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC
Study NCT01050998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mavrilimumab 10 mg
Description: Mavrilimumab (CAM-3001) 10 mg injection subcutaneously every other week for 12 weeks.
Study NCT01050998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mavrilimumab 30 mg
Description: Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every other week for 12 weeks.
Study NCT01050998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mavrilimumab 50 mg
Description: Mavrilimumab (CAM-3001) 50 mg injection subcutaneously every other week for 12 weeks.
Study NCT01050998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mavrilimumab 100 mg
Description: Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every other week for 12 weeks.
Study NCT01050998 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to mavrilimumab injection subcutaneously every other week for 12 weeks.
Study NCT02287831 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord mesenchymal stem cells
Study NCT04176172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Participants will receive open-label varenicline for 12 weeks.
Study NCT00003199 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC
Study NCT00003199 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo autologous peripheral blood stem cell infusion
Study NCT04176172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Participants will receive open-label varenicline for 12 weeks.
Study NCT04176172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Participants will receive open-label nicotine patch for 12 weeks. (Participants in the NMR-tailored treatment arms will receive either varenicline OR patch; they will not receive both)